Acadian Asset Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $651M | Buy |
11,797,085
+2,832,926
| +32% | +$154M | 0.92% | 23 |
|
|
2025
Q4 | $440M | Buy |
8,964,159
+6,175,701
| +221% | +$288M | 0.72% | 30 |
|
|
2025
Q3 | $120M | Sell |
2,788,458
-36,287
| -1% | -$1.42M | 0.21% | 103 |
|
|
2025
Q2 | $108M | Sell |
2,824,745
-1,157,579
| -29% | -$44.2M | 0.22% | 100 |
|
|
2025
Q1 | $154M | Buy |
3,982,324
+2,663,270
| +202% | +$97.5M | 0.44% | 56 |
|
|
2024
Q4 | $44.6M | Sell |
1,319,054
-2,747,133
| -68% | -$98.9M | 0.13% | 162 |
|
|
2024
Q3 | $166M | Buy |
4,066,187
+2,355,935
| +138% | +$96.4M | 0.52% | 41 |
|
|
2024
Q2 | $65.8M | Sell |
1,710,252
-509,546
| -23% | -$21.4M | 0.2% | 119 |
|
|
2024
Q1 | $95.1M | Buy |
2,219,798
+1,426,935
| +180% | +$58.8M | 0.33% | 86 |
|
|
2023
Q4 | $29.4M | Sell |
792,863
-551,668
| -41% | -$19.8M | 0.11% | 162 |
|
|
2023
Q3 | $48.7M | Sell |
1,344,531
-2,862,669
| -68% | -$102M | 0.2% | 128 |
|
|
2023
Q2 | $150M | Sell |
4,207,200
-736,087
| -15% | -$26.4M | 0.62% | 34 |
|
|
2023
Q1 | $176M | Sell |
4,943,287
-1,612,345
| -25% | -$56.4M | 0.77% | 17 |
|
|
2022
Q4 | $230M | Buy |
6,555,632
+43,870
| +0.7% | +$1.46M | 1.13% | 7 |
|
|
2022
Q3 | $192M | Sell |
6,511,762
-2,072,441
| -24% | -$78.5M | 1.05% | 12 |
|
|
2022
Q2 | $467M | Buy |
8,584,203
+5,864,193
| +216% | +$324M | 2.39% | 3 |
|
|
2022
Q1 | $148M | Buy |
2,720,010
+1,289,519
| +90% | +$70M | 0.61% | 39 |
|
|
2021
Q4 | $78.8M | Buy |
1,430,491
+1,184,393
| +481% | +$61.6M | 0.29% | 96 |
|
|
2021
Q3 | $11.7M | Buy |
246,098
+84,023
| +52% | +$4.22M | 0.04% | 280 |
|
|
2021
Q2 | $8.07M | Sell |
162,075
-1,136,795
| -88% | -$54.6M | 0.03% | 360 |
|
|
2021
Q1 | $57.9M | Buy |
+1,298,870
| New | +$59M | 0.23% | 110 |
|
|
2018
Q2 | – | Sell |
-6,307
| Closed | -$310K | – | 1760 |
|
|
2018
Q1 | $310K | Sell |
6,307
-29,427
| -82% | -$1.37M | ﹤0.01% | 964 |
|
|
2017
Q4 | $1.58M | Buy |
35,734
+22,553
| +171% | +$1.04M | 0.01% | 599 |
|
|
2017
Q3 | $669K | Buy |
+13,181
| New | +$669K | ﹤0.01% | 744 |
|
|
2017
Q1 | – | Sell |
-533
| Closed | -$26K | – | 1642 |
|
|
2016
Q4 | $26K | Hold |
533
| – | – | ﹤0.01% | 1275 |
|
|
2016
Q3 | $29K | Sell |
533
-601
| -53% | -$33K | ﹤0.01% | 1129 |
|
|
2016
Q2 | $61K | Buy |
+1,134
| New | +$59.7K | ﹤0.01% | 1084 |
|
|
2014
Q4 | – | Sell |
-1,852
| Closed | -$106K | – | 1289 |
|
|
2014
Q3 | $106K | Buy |
1,852
+78
| +4% | +$4.78K | ﹤0.01% | 826 |
|
|
2014
Q2 | $119K | Buy |
+1,774
| New | +$120K | ﹤0.01% | 845 |
|
Other funds holding GSK
JEST
Acadian Asset Management's GSK Position: Q1 2026 in Review
Acadian Asset Management increased its GSK (GSK) stake by 32% in Q1 2026, buying an estimated $154M and bringing the position to 11,797,085 shares worth $651M. The position accounts for 0.92% of the portfolio, ranked #23.
Acadian Asset Management first reported a position in GSK in Q2 2014 and has held it in 29 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Acadian Asset Management held 11,797,085 shares of GSK worth $651M as of Q1 2026.
- Acadian Asset Management bought 2,832,926 GSK shares in Q1 2026, an estimated $154M.
- GSK made up 0.92% of Acadian Asset Management's portfolio in Q1 2026, its #23 holding.
- Acadian Asset Management first reported a position in GSK in Q2 2014 and has held it in 29 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.